Interv Akut Kardiol 2012; 11(5-6): 192-195

Pompe disease as seen by a pediatric cardiologist

Veronika Stará
Kardiologická ambulance, Pediatrická klinika FN Motol, Praha

Pompe disease is rare, autosomal recessive disorder, caused by deficiency of enzyme acid-alpha-glucosidase that plays important role

in glycogen metabolism. The lack of enzyme leads to abnormal glycogen storage in different tissues. Skeletal and cardiac muscles are

predominantly affected, though accumulation in liver and endothelial cells is also common.

The clinical presentation of disease varies by age – in infancy is characterized by severe generalized hypotonia, failure to thrive and hypertrophic

cardiomyopathy, in some cases accompanied with obstruction of left ventricular outflow tract or with different arrhythmias.

In childhood and adulthood dominates muscular weakness and respiratory problems, cardiac involvement is unusual. Prognosis of

infantile form is poor, patients usually die within two years of age. The cause of the death is uncontrollable cardiopulmonary failure. The

progression of the disease at late onset form is slower and cardiac involvement is unusual, but still the natural clinical course of disease

is unfavorable and tend to the respiratory failure and patient´s disability. This article points out to cardiovascular aspects of disease,

it´s clinical presentation, diagnosis, differential diagnosis and therapeutic options.

Keywords: Pompe disease, hypotonia, muscle weakness, hypertrophic cardiomyopathy, enzymatic substitution therapy

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stará V. Pompe disease as seen by a pediatric cardiologist. Interv Akut Kardiol. 2012;11(5-6):192-195.
Download citation

References

  1. Anderson WE. Glycogen Storage Disease, Type II (Pompe Disease). [online] Dostupné z: http://emedicine.medscape.com/article/119506-overview.
  2. Malinová V. Glykogenóza II. typu (GSD II, m. Pompe). Současné možnosti diagnostiky a terapie. Klinická kazuistika. Neurol. prax 2010; 11(5): 326-330.
  3. Ibrahim J, McGovern MM. Genetics of Glycogen-Storage Disease Type II (Pompe Disease). [online] Dostupné z: http://emedicine.medscape.com/article/947870-overview.
  4. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999; 7(6): 713-716. Go to original source... Go to PubMed...
  5. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006; 8: 267-288. Go to original source... Go to PubMed...
  6. Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006; 148: 671-676. Go to original source... Go to PubMed...
  7. Limongelli G, Fratta F. Cardiovascular involvement in Pompe disease. Proceedings of the Meeting Course on Type II Glycogenosis: a network for the treatment of Pompe disease.
  8. Van Maldergem L, Haumont D, Saurty D, et al. Bradycardia in a case of type II glycogenosis (Pompe's disease) revealing in early neonatal period. Acta Clin Belg. 1990; 45(6): 412-414. Go to original source... Go to PubMed...
  9. Fung KP, Lo RN, Ho HC. Pompe's disease presenting as supraventricular tachycardia. Aust Paediatr J. 1989; 25(2): 101-102. Go to original source... Go to PubMed...
  10. Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J. Aug 1978; 96(2): 246-252. Go to original source... Go to PubMed...
  11. Arad M, Moskowitz IP, Patel VV, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson- White syndrome in glycogen storage cardiomyopathy. Circulation 2003; 107: 2850-2856. Go to original source... Go to PubMed...
  12. Hagemans ML, et al. Clinical manifestation and natural course OF late-onset Pompe´s disease in 54 Dutch patiens. Brain 2005; 128: 671. Go to original source... Go to PubMed...
  13. Forsha D, Li JS, Smith PB, et al. Cardiovascular abnormalities in late onset Pompe disease and response to enzyme replacement therapy. Genet Med.
  14. Soliman OII. Cardiac involvement in adults with Pompe disease. Journal of Internal Medicine 264; 333-339 339.
  15. Ben-Ami R, et al. The Mount Sinai Hospital Clinicopathological Conference: A 45-year-old manwith Pompe's disease and dilated cardiomyopathy, MT SINAI J, 2001; 68(3): 205-212.
  16. Güngör D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011; 1(6): 34. Go to original source... Go to PubMed...
  17. Nemes A, Soliman OI, Geleijnse ML, et al. Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). Int J Card 2007; 120: 138-141. Go to original source... Go to PubMed...
  18. Makos MM, McComb RD, Hart MN, et al. Alpha - glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol 1987; 22: 629-633. Go to original source... Go to PubMed...
  19. Kretzschmar HA, Wagner H, Hübner G, et al. Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci 1990; 98: 169-183. Go to original source... Go to PubMed...
  20. Ansong AK, Li JS, Nozik-Grayck E, et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med. 2006; 8: 297-301. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.